Rehospitalization Risk with Second-Generation and Depot Antipsychotics

References

• Atakan Z, Cliff G, Cooper JE: Can psychiatrists predict the one-year outcome of schizophrenia? Soc Psychiatry Psychiatr Epidemiol 1990; 25(3):117–124
   Google Scholar
• Olfson M, Mechanic D, Boyer CA, Hansell S. Walkup J, Weiden PJ: Assessing clinical predictions of early rehospital-ization in schizophrenia. J Nerv Ment Dis 1999; 187(12):721–729
   PubMed Web of Science ®Google Scholar
• Russo J, Roy-Byrne P. Jaffe C, Ries R, Dagadakis C, Avery D: Psychiatric status, quality of life, and level of care as predictors of outcomes of acute inpatient treatment. Psychiatr Serv 1997; 48(11):1427–1434
   Web of Science ®Google Scholar
• Swett C: Symptom severity and number of previous psychiatric admissions as predictors of readmission. Psychiatr Serv 1995; 46(5):482–485
   Google Scholar
• Gupta S. Hendricks S. Kenkel AM, Bhatia SC, Haffke EA: Relapse in schizophrenia: Is there a relationship to substance abuse?. Schizophr Res 1996; 20:153–156
   Google Scholar
• Sullivan G, Wells KB, Morgenstern H, Leake B: Identifying modifiable risk factors for rehospitalization: A case control study of seriously mental ill persons in Mississippi. Am J Psy-chiatry 1995; 152(12):1749–1756
   PubMed Web of Science ®Google Scholar
• Neale MS, Rosenheck RA: Therapeutic alliance and outcome in a VA intensive case management program. Psychiatr Serv 1995; 46(7):719–721
   PubMed Web of Science ®Google Scholar
• Vaughn CE, Leff JP: The influence of family and social fac-tors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129:125–137
   Google Scholar
• Weiden P. Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57\(Suppl. 11):53–60
   Google Scholar
• Gerlach J: Depot neuroleptics in relapse prevention: Avan-tages and disadvantages. Int Clin Psychopharmacol 1995; 9(Suppl 5):17–20
   PubMed Web of Science ®Google Scholar
• Barnes TR, Curson DA: Long-term depot antipsychotics. A risk—benefit assessment. Drug Saf 1994; 10(6):464–479
   Google Scholar
• Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB: Prevention of relapse in schizophre-nia. An evaluation of fluphenazine decanoate. Arch Gen Psy-chiatry 1980; 37(1):16–24
   PubMedGoogle Scholar
• Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J. Racagni G, Carulla LS, Schooler NR: Guidelines for depot an-tipsychotic treatment in schizophrenia. European Neuropsy-chopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8(1):55–66
   Google Scholar
• Lehman AF, Steinwachs DM: At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24:1–10
   PubMed Web of Science ®Google Scholar
• Miller AL, Chiles IA, Chiles JK, Crismon ML, Rush AJ, Shon SP: The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999; 60:649–657
   PubMed Web of Science ®Google Scholar
• Citrome L, Levine I. Allingham B: Utilization of depot neu-roleptic medication in psychiatric inpatients. Psychopharma-col Bull 1996; 32(3):321–326
   Google Scholar
• Kuno E, Rothbard AB: Racial disparities in antipsychotic pre-scription patterns for patients with schizophrenia. Am J Psy-chiatry 2002; 159:567–572
   PubMed Web of Science ®Google Scholar
• Tavcar R, Dernovsek MZ, Zvan V: Choosing antipsychotic maintenance therapy—A naturalistic study. Pharmacopsychi-atry 2000; 33(21:66–71
   Google Scholar
• Jibson MD, Tandon R: New atypical antipsychotic medica-tions. J Psychiatr Res 1998; 32:215–228
   PubMed Web of Science ®Google Scholar
• Gaebel W: Towards the improvement of compliance: The sig-nificance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 1997; 12(Suppl 1):S37—S42
   Google Scholar
• Tran PV, Dellva MA, Tollefson GD, Wently AL, Beasley CM, Jr: Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychi-atry 1998; 172:499–505
   PubMed Web of Science ®Google Scholar
• Conley RR, Love RC, Kelly DL, Bartko JJ: Rehospitalization rates of patients recently discharged on a regimen of risperi-done or clozapine. Am J Psychiatry 1999; 156:863–868
   PubMed Web of Science ®Google Scholar
• Essock SM, Hargreaves WA, Covell NH, Goethe J: Clozap-ine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 1996; 32(4):683–697
   PubMedGoogle Scholar
• Hogarty GE: Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 1993; 54(Suppl 3):18–23
   Google Scholar
• Rabinowitz J, Licthenberg P. Kaplan Z, Mark M, Nahon D, Davidson M: Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158:266–269
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Ulrich RF: The limitations of antipsychotic med-ication on schizophrenia relapse and adjustment and the con-tributions of psychosocial treatment. J Psychiatr Res 1998; 32:243–250
   PubMed Web of Science ®Google Scholar
• Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG: Relapse and rehospitalization during maintenance treat-ment of schizophrenia. The effects of dose reduction and fam-ily treatment. Arch Gen Psychiatry 1997; 54(5):453–463
   PubMed Web of Science ®Google Scholar
• Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR: Re-hospitalization rates for depot antipsychotics and pharma-coeconomic implications: Comparison with risperidone. Am J Health Syst Pharm 1998; 55\(Supp14):17–19
   Google Scholar
• Kaplan EL, Meier P: Nonparametric estimation from incom-plete observations. J Am Stat Assoc 1958; 53:457–481
   Web of Science ®Google Scholar
• Prentice RL: Linear rank tests with right censored data. Biometrika 1978; 65:167–179
   Web of Science ®Google Scholar
• Cox DR: Regression models with life tables. J R Stat Soc 1972; 34:187–220
   Google Scholar
• Aickin M, Gensler H: Adjusting for multiple testing when re-porting research results: The Bonferroni vs. Holm methods. Am J Public Health 1996; 86:726–728
   PubMed Web of Science ®Google Scholar
• Kane .1, Honigfeld G. Singer J. Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9):789–796
   Google Scholar
• Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23(4):663–674
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G: The effects of risperi-done on the five dimensions of schizophrenia derived by fac-tor analysis: Combined results of the North American trials. J Clin Psychiatry 1997; 58(12):538–546
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM: Negative symptoms: A path an-alytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am .1 Psychiatry 1997; 154(4):466–474
   Google Scholar
• Patel NC, Dorson PG, Edwards N, Mendelson S. Crismon ML: One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002; 53:891–893
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Engelhart L, 011endorf D, Oster G: The Risperi-done Outcomes Study of Effectiveness (ROSE): A model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 1999; 60(Suppl 3):42–47
   PubMed Web of Science ®Google Scholar
• Desai NM, Huq Z, Martin SD, McDonald G: Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia. The schizophrenia treat-ment and assessment group. Adv Ther 1999; 16(2):78–88
   Google Scholar
• McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS: Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry 1987; 151:333–336
   Google Scholar
• Bransgrove LL, Kelly NW: Movement disorders in patients treated with long-acting injectable antipsychotic drugs. Am J Hosp Pharm 1994; 51(7):895–899
   Google Scholar
• Masimiremba CM, Hasler JA: Genetic polymorphism of drug metabolism enzymes in African populations: Implications for the use of neuroleptics and antidepressants, Brain Res Bull 1997; 44(5):561–571
   Google Scholar
• Bertilsson L: Geographical/interracial differences in poly-morphic drug oxidation, current state of knowledge of cy-tochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192–209
   PubMed Web of Science ®Google Scholar
• Tunnicliffe S. Harrison G, Standen PJ: Factors affecting compliance with depot injection treatment in the commu-nity. Soc Psychiatry Psychiatr Epidemiol 1992; 27(5):230–233
   Google Scholar
• Segal SP, Bola JR, Watson MA: Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996; 47(3):282–286
   PubMed Web of Science ®Google Scholar
• Glazer WM, Morganstern H, Doucette J: Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994; 45(1):38–42
   Google Scholar
• Treatment of schizophrenia 1999. The expert consensus guide-line series. J Clin Psychiatry 1999; 60(Suppl 11):3–80
   Google Scholar